The most consequential weight-loss decision in America may be made in a benefits meeting rather than a doctor’s office. Employers are confronting a difficult equation: GLP-1 medicines can deliver meaningful clinical benefits, but the cost of covering them appears on pharmacy budgets long before potential savings show up in medical claims.
A Business Group on Health survey released in May 2026 found that 67% of participating employers covered GLP-1 medicines for weight management. Among those offering coverage, only 72% said they were likely to continue it in 2027. A separate survey released in August reported that 60% of its respondents covered GLP-1s for obesity in 2026. Those findings come from different employer samples, but together they show why the benefits conversation is becoming harder.
Two Surveys, One Uncomfortable Coverage Question
The May report was based on responses from 105 Business Group on Health employer members surveyed in February and March. Its 67% coverage figure was a snapshot of that group. Of employers already covering GLP-1s for weight management, 72% expected to continue in 2027, while 10% expected not to. Those were intentions at the time of the survey, not finalized plan decisions or a prediction of how many workers would lose access.
Then came the August 25 release of the group’s 2027 Employer Healthcare Strategy Survey. Based on 127 employers responding in June, it reported that coverage for obesity was down from 72% in its 2025 comparison to 60% in 2026. The two 2026 survey figures, 67% and 60%, should not be subtracted as though the same employers were interviewed twice. But the later results make it impossible to describe coverage confidence as merely a future concern.
The Pharmacy Bill Arrives Before the Health Savings
Employers are reacting to a financial asymmetry. Drug spending is visible in current invoices. Potential long-term benefits from treating obesity-related illness may take years to emerge and can be hard to isolate in aggregated claims data. Nearly eight in ten respondents in the May GLP-1 survey said the medicines were driving increases in company healthcare costs. More than half of employers covering them anticipated significant clinical benefits, but relatively few had yet seen population-level changes such as fewer bariatric surgeries.
That absence is not proof that treatment has no value. It could reflect the duration of follow-up, the population being measured or the limits of employer claims reporting. Equally, a plausible future reduction in heart disease or disability is not a guaranteed saving for a particular employer.
The August strategy survey provided the larger budget backdrop: respondents projected a median healthcare cost trend increase of 9.2% for 2027 before plan changes, potentially reduced to 8% afterward. Pharmacy represented about one-quarter of employer healthcare spending. GLP-1 use was one contributing pressure, alongside broader drug and medical costs.
The drug bill arrives this year. The hoped-for health dividend may arrive much later.
Coverage on Paper Is Not Access in Practice
Rather than simply dropping coverage, many employers are tightening its conditions. The May survey described strategies such as verification of clinical eligibility, required weight-management program participation, restrictions on prescribers and narrower formularies. Some measures can support appropriate prescribing. They can also create paperwork, delays and appeals for patients whose clinicians consider treatment appropriate.
For a worker, saying a GLP-1 is covered does not answer the questions that matter: for which diagnosis, at which dose, under what eligibility requirements, through which prescriber and at what out-of-pocket cost? A medication can be on a formulary yet remain difficult to obtain. Employers should distinguish a defensible utilization policy from an administrative obstacle course.
Oral GLP-1 Medicines Could Make the Math Harder
New dosage forms introduce another uncertainty. In the May survey, 87% of respondents expected oral GLP-1 options to increase overall demand, while only 9% anticipated lower prices. Those percentages describe employer expectations, not demonstrated effects on the eventual cost of treatment.
Pills may appeal to people who prefer not to inject medication. But convenience does not automatically translate into lower health-plan spending. If more people begin treatment, and many need continued therapy, a cheaper price per prescription could still coexist with a larger total pharmacy budget. That is the distinction between affordability for an individual and sustainability for a plan.
The Value Argument Needs More Than a Weight-Loss Number
Employers need evidence that extends beyond short-term weight loss. Relevant outcomes might include glycemic control, cardiovascular health, functioning, quality of life and reductions in costly disease complications. But these outcomes do not mature on the same timeline, and evidence from clinical trials cannot simply be treated as a forecast of savings in one company’s workforce.
A one-year budget can overlook meaningful clinical gains. A speculative ten-year savings model can overstate what is known. Responsible purchasing requires both: transparent measures of near-term costs and realistic assumptions about long-term health outcomes.
The 2027 Test Is About Financing, Not Whether Obesity Matters
The bigger story is not that employers have decided obesity treatment is unimportant. It is that an effective class of therapies is colliding with a financing system shaped by annual budgets, turnover and shifting benefit designs. The May survey showed uncertainty over continued coverage; the August survey showed that the squeeze was already evident in a newer employer sample.
For patients and clinicians, the immediate implication is to check the actual plan rules rather than rely on the phrase “GLP-1 covered.” For employers, the obligation is more difficult: make eligibility rules clinically defensible, explain them clearly and measure value without pretending future savings are guaranteed.
Coverage remains common among these large employers. Confidence about paying for it on the same terms does not. The 2027 benefits cycle is where that tension becomes a real decision.
Sources: Business Group on Health GLP-1 Survey (May 5, 2026); 2027 Employer Healthcare Strategy Survey (August 25, 2026).
